SCHEMBL6385170

SCHEMBL6385170

Cc1sc(N)nc1-c1cccc2ccccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 5/20 0.55
MPL P40238 1/20 0.55
TGFBR1 P36897 1/20 0.54
DRD2 P14416 1/20 0.49
DHFR P00374 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.44
LMNA P02545 2/20 0.43
MEN1 O00255 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43
RECQL P46063 1/20 0.43
MMP14 P50281 1/20 0.43
KMT2A Q03164 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NPY5R Q15761 1/20 0.41
NISCH Q9Y2I1 1/20 0.41
CHEK1 O14757 1/20 0.41
DAPK3 O43293 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23610344 0.83 HTR6 (0.49) HTR6MPLDRD2SMN1; SMN2LMNA
SCHEMBL8472396 0.83 NISCH (0.44) HTR6TGFBR1DHFRSMN1; SMN2LMNA
SCHEMBL28902429 0.81 MPL (0.55) HTR6MPLDRD2SMN1; SMN2LMNA
SCHEMBL23610339 0.80 TGFBR1 (0.54) HTR6MPLTGFBR1DHFRSMN1; SMN2
SCHEMBL23610349 0.80 TGFBR1 (0.54) HTR6TGFBR1DHFRLMNAMEN1
SCHEMBL23618147 0.80 MPL (0.57) HTR6MPLTGFBR1DHFRSMN1; SMN2
SCHEMBL6389273 0.80 TGFBR1 (0.53) HTR6TGFBR1DHFRSMN1; SMN2LMNA
SCHEMBL30256985 0.78 MYC (0.56) HTR6MPLDRD2SMN1; SMN2LMNA
SCHEMBL28357048 0.77 TGFBR1 (0.57) TGFBR1DHFRSMN1; SMN2LMNAMEN1
SCHEMBL23618152 0.76 TGFBR1 (0.50) HTR6MPLTGFBR1DHFRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050154031-A1 5-Ht2b receptor antagonists PHARMAGENE LABORATORIES LIMITED (GB) 2005-07-14 US disclosed
CN-1633293-A 5-ht2b receptor antagonists PHARMAGENE LAB LTD (GB) 2005-06-29 CN disclosed
EP-1474141-A1 5-HT2B RECEPTOR ANTAGONISTS Pharmagene Laboratories Ltd (GB) 2004-11-10 EP disclosed
WO-2003068227-A1 5-HT2B RECEPTOR ANTAGONISTS PHARMAGENE LABORATORIES LIMITED (GB) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154031-A1 5-Ht2b receptor antagonists HTR2B, HTR3B, HTR7 HTR6 6/4885MPL 1218/4885TGFBR1 560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.